

# John Z Metcalfe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10540269/publications.pdf>

Version: 2024-02-01

27  
papers

1,854  
citations

567281

15  
h-index

526287

27  
g-index

27  
all docs

27  
docs citations

27  
times ranked

2724  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. <i>Clinical Microbiology Reviews</i> , 2014, 27, 3-20.	13.6	662
2	Interferon-Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Individuals: A Systematic Review and Meta-Analysis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 230-238.	2.1	260
3	Interferon- $\gamma$ Release Assays for Active Pulmonary Tuberculosis Diagnosis in Adults in Low- and Middle-Income Countries: Systematic Review and Meta-analysis. <i>Journal of Infectious Diseases</i> , 2011, 204, S1120-S1129.	4.0	241
4	Test Variability of the QuantiFERON-TB Gold In-Tube Assay in Clinical Practice. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 206-211.	5.6	155
5	Genotyping of <i>Mycobacterium tuberculosis</i> : application in epidemiologic studies. <i>Future Microbiology</i> , 2011, 6, 203-216.	2.0	99
6	Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. <i>The Lancet Global Health</i> , 2019, 7, e191-e199.	6.3	53
7	<i>Mycobacterium tuberculosis</i> Subculture Results in Loss of Potentially Clinically Relevant Heteroresistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	38
8	Cryptic Microheteroresistance Explains <i>Mycobacterium tuberculosis</i> Phenotypic Resistance. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1191-1201.	5.6	37
9	Genomic Epidemiology of Multidrug-Resistant <i>Mycobacterium tuberculosis</i> During Transcontinental Spread. <i>Journal of Infectious Diseases</i> , 2015, 212, 302-310.	4.0	34
10	Evaluation of Quantitative IFN- $\gamma$ Response for Risk Stratification of Active Tuberculosis Suspects. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 87-93.	5.6	32
11	Genetic variants and their association with phenotypic resistance to bedaquiline in <i>Mycobacterium tuberculosis</i> : a systematic review and individual isolate data analysis. <i>Lancet Microbe</i> , The, 2021, 2, e604-e616.	7.3	32
12	Microscopic-Observation Drug-Susceptibility Assay for the Diagnosis of Drug-Resistant Tuberculosis in Harare, Zimbabwe. <i>PLoS ONE</i> , 2013, 8, e55872.	2.5	23
13	Determinants of Multidrug-Resistant Tuberculosis Clusters, California, USA, 2004–2007. <i>Emerging Infectious Diseases</i> , 2010, 16, 1403-1409.	4.3	20
14	Drug-Resistant Tuberculosis in High-Risk Groups, Zimbabwe. <i>Emerging Infectious Diseases</i> , 2014, 20, 135-7.	4.3	19
15	Suboptimal specificity of Xpert MTB/RIF among treatment-experienced patients. <i>European Respiratory Journal</i> , 2015, 45, 1504-1506.	6.7	19
16	Catastrophic costs among tuberculosis-affected households in Zimbabwe: A national health facility-based survey. <i>Tropical Medicine and International Health</i> , 2021, 26, 1248-1255.	2.3	18
17	Moving Beyond Directly Observed Therapy for Tuberculosis. <i>PLoS Medicine</i> , 2015, 12, e1001877.	8.4	17
18	Empiric tuberculosis treatment in retreatment patients in high HIV/tuberculosis-burden settings. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 794-795.	9.1	15

#	ARTICLE	IF	CITATIONS
19	Prevalence of drug-resistant tuberculosis in Zimbabwe: A health facility-based cross-sectional survey. <i>International Journal of Infectious Diseases</i> , 2019, 87, 119-125.	3.3	14
20	Xpert MTB/RIF False Detection of Rifampin-Resistant Tuberculosis from Prior Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1316-1318.	5.6	12
21	Tuberculosis progression rates in U.S. Immigrants following screening with interferon-gamma release assays. <i>BMC Public Health</i> , 2016, 16, 875.	2.9	11
22	Minority Mycobacterium tuberculosis Genotypic Populations as an Indicator of Subsequent Phenotypic Resistance. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 61, 789-791.	2.9	11
23	Xpert Mycobacterium tuberculosis/Rifampicin-“Detected Rifampicin Resistance is a Suboptimal Surrogate for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications. <i>Clinical Infectious Diseases</i> , 2020, 73, e362-e370.	5.8	11
24	Distinct lung microbiota associate with HIV-associated chronic lung disease in children. <i>Scientific Reports</i> , 2020, 10, 16186.	3.3	7
25	Health care seeking patterns of rifampicin-resistant tuberculosis patients in Harare, Zimbabwe: A prospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0254204.	2.5	7
26	Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis. <i>Journal of Clinical Microbiology</i> , 2022, 60, JCM0190721.	3.9	6
27	Analysis of Green Light Committee Implementation and Acquisition of Second-line Drug Resistance. <i>Clinical Infectious Diseases</i> , 2015, 60, 970-970.	5.8	1